levosimendan Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
cardiac stimulants, pimobendan derivatives 1576 141505-33-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • levosimendan
  • (R)-Simendan
  • simdax
A hydrazone and pyridazine derivative; the levo-form is a phosphodiesterase III inhibitor, calcium-sensitizing agent, and inotropic agent that is used in the treatment of HEART FAILURE.
  • Molecular weight: 280.29
  • Formula: C14H12N6O
  • CLOGP: 1.90
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 2
  • TPSA: 113.43
  • ALOGS: -3.50
  • ROTB: 3

Drug dosage:

DoseUnitRoute
11 mg P

ADMET properties:

PropertyValueReference
BA (Bioavailability) 85 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.24 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 3.80 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.02 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.10 hours Lombardo F, Berellini G, Obach RS

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Lymphatic fistula 120.98 89.97 21 1436 877 53346732
Femoral hernia incarcerated 120.66 89.97 21 1436 891 53346718
Pancreatic steatosis 116.74 89.97 21 1436 1078 53346531
Arterial haemorrhage 112.79 89.97 22 1435 1754 53345855
Wound infection pseudomonas 110.69 89.97 21 1436 1446 53346163
Cardiogenic shock 103.38 89.97 32 1425 17450 53330159
Seroma 102.54 89.97 21 1436 2144 53345465
Haemarthrosis 99.40 89.97 22 1435 3248 53344361
Aortic valve stenosis 99.28 89.97 22 1435 3266 53344343
Tachyarrhythmia 91.39 89.97 22 1435 4694 53342915

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event

Pharmacologic Action:

SourceCodeDescription
ATC C01CX08 CARDIOVASCULAR SYSTEM
CARDIAC THERAPY
CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
Other cardiac stimulants
MeSH PA D002316 Cardiotonic Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D058987 Phosphodiesterase 3 Inhibitors
MeSH PA D010726 Phosphodiesterase Inhibitors
MeSH PA D020011 Protective Agents
MeSH PA D014665 Vasodilator Agents
CHEBI has role CHEBI:35620 vasodilator
CHEBI has role CHEBI:38070 antiarrhythmic agent
CHEBI has role CHEBI:38147 cardiotonic drugs
CHEBI has role CHEBI:50568 cyclic nucleotide phosphodiesterase inhibitor

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Congestive heart failure indication 42343007 DOID:6000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 6.04 acidic
pKa2 11.34 acidic
pKa3 4.67 Basic
pKa4 4.04 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Troponin C, slow skeletal and cardiac muscles Cytosolic other OPENER Kd 3.16 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
cGMP-inhibited 3',5'-cyclic phosphodiesterase A Enzyme WOMBAT-PK
ATP-sensitive inward rectifier potassium channel 11 Ion channel WOMBAT-PK
ATP-sensitive inward rectifier potassium channel 8 Ion channel WOMBAT-PK

External reference:

IDSource
D04720 KEGG_DRUG
C0246904 UMLSCUI
CHEBI:50567 CHEBI
CHEMBL2051955 ChEMBL_ID
DB00922 DRUGBANK_ID
D000077464 MESH_DESCRIPTOR_UI
3033825 PUBCHEM_CID
7020 INN_ID
C6T4514L4E UNII
73107 RXNORM
009718 NDDF
442790008 SNOMEDCT_US
442795003 SNOMEDCT_US

Pharmaceutical products:

None